[Comparative analysis of 3 therapeutic regimens based on the combination of an anthracycline and cytosine arabinoside for remission induction in myeloblastic leukemia].
Sanz
M A
MA
Lorenzo
J I
JI
Sanz
G F
GF
Martín Aragonés
G
G
Rafecas
F J
FJ
Martínez
J A
JA
Gomis
F
F
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D013866:Thioguanine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D003561:Cytarabine; D014750:Vincristine; D004317:Doxorubicin; D013866:Thioguanine; D011241:Prednisone; D003630:Daunorubicin
Análisis comparativo de tres regímenes terapéuticos basados en la combinación de una antraciclina y arabinósido de citosina para la inducción a la remisión en la leucemia mieloblástica.